Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. by McKerrell, Thomas et al.
e-Blood
MYELOID NEOPLASIA
Development and validation of a comprehensive genomic diagnostic tool
for myeloid malignancies
Thomas McKerrell,1-3 Thaidy Moreno,4 Hannes Ponstingl,1 Niccolo Bolli,1,5 Joa˜o M. L. Dias,6 German Tischler,1
Vincenza Colonna,1,7 Bridget Manasse,2 Anthony Bench,2 David Bloxham,2 Bram Herman,8 Danielle Fletcher,8 Naomi Park,1
Michael A. Quail,1 Nicla Manes,1,3 Clare Hodkinson,3 Joanna Baxter,3 Jorge Sierra,9 Theodora Foukaneli,2
Alan J. Warren,2,3,10,11 Jianxiang Chi,12,13 Paul Costeas,12,13 Roland Rad,14,15 Brian Huntly,2,3,10,11 Carolyn Grove,16,17
Zemin Ning,1 Chris Tyler-Smith,1 Ignacio Varela,4 Mike Scott,2,3 Josep Nomdedeu,9 Ville Mustonen,1 and
George S. Vassiliou1-3
1Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; 2Department of Haematology, Haemato-oncology Diagnostic Service, Cambridge
University Hospitals National Health Service Trust, Cambridge, United Kingdom; 3Department of Haematology, University of Cambridge, Cambridge, United
Kingdom; 4Instituto de Biomedicina y Biotecnologı´a de Cantabria, Cantabria, Spain; 5Division of Haematology, Fondazione IRCCS Istituto Nazionale dei
Tumori, University of Milan, Milan, Italy; 6Cancer Molecular Diagnosis Laboratory, National Institute for Health Research Cambridge Biomedical Research
Centre, Cambridge, United Kingdom; 7National Research Council, Institute of Genetics and Biophysics, Naples, Italy; 8Agilent Technologies, Cheadle,
United Kingdom; 9Department of Haematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; 10Cambridge Institute for Medical Research,
Cambridge, United Kingdom; 11Wellcome Trust–Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United
Kingdom; 12The Center for the Study of Haematological Malignancies, Nicosia, Cyprus; 13The Karaiskakio Foundation, Nicosia, Cyprus; 14Department of
Medicine II, Klinikum Rechts der Isar, Technische Universita¨t Mu¨nchen, Munich, Germany; 15German Cancer Consortium, German Cancer Research
Center, Heidelberg, Germany; 16Department of Haematology, PathWest/Sir Charles Gairdner Hospital, Perth, Australia; and 17Pathology and Laboratory
Medicine, University of Western Australia, Perth, Australia
Key Points
• We develop and validate
Karyogene, a comprehensive
one-stop diagnostic platform
for the genomic analysis of
myeloid malignancies.
• Karyogene simultaneously
detects substitutions,
insertions/deletions,
translocations, copy number
and zygosity changes in a
single assay.
The diagnosis of hematologic malignancies relies on multidisciplinary workflows
involving morphology, flow cytometry, cytogenetic, and molecular genetic analyses.
Advances in cancer genomics have identified numerous recurrent mutations with clear
prognostic and/or therapeutic significance to different cancers. Inmyeloidmalignancies,
there is a clinical imperative to test for suchmutations inmainstreamdiagnosis; however,
progress toward this has been slow and piecemeal. Here we describe Karyogene, an
integrated targeted resequencing/analytical platform that detects nucleotide substitu-
tions, insertions/deletions, chromosomal translocations, copy number abnormalities,
and zygosity changes in a single assay. We validate the approach against 62 acute
myeloid leukemia, 50 myelodysplastic syndrome, and 40 blood DNA samples from
individualswithout evidenceof clonal blooddisorders.Wedemonstrate robust detection
of sequence changes in 49 genes, including difficult-to-detect mutations such as FLT3
internal-tandem and mixed-lineage leukemia (MLL) partial-tandem duplications, and
clinically significant chromosomal rearrangements including MLL translocations to
known and unknown partners, identifying the novel fusion gene MLL-DIAPH2 in the
process. Additionally, we identify most significant chromosomal gains and losses, and several copy neutral loss-of-heterozygosity
mutations at a genome-wide level, including previously unreported changes such as homozygosity for DNMT3A R882 mutations.
Karyogene represents a dependable genomic diagnosis platform for translational research and for the clinical management of
myeloid malignancies, which can be readily adapted for use in other cancers. (Blood. 2016;128(1):e1-e9)
Introduction
Advances in genomics have defined many of the clinically significant
gene mutations in human cancers. In the myeloid malignancies acute
myeloid leukemia (AML) and the related myelodysplastic syndromes
(MDS), individual cancers harbor a small number of driver mutations,
however more than 50 genes are recurrently mutated across cases.
Additionally, as in other cancers, the nature of mutations is diverse
and ranges from nucleotide (nt) substitutions and insertions/
deletions (indels), to large-scale changes such as chromosomal
deletions, duplications, and translocations. Because many of these
changes influence patient prognosis and/or predict response to
therapy, their detection at the time of diagnosis represents an important
clinical need.
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To address this need, a number of methodologies for the simulta-
neous analysis of multiple target genes have been developed.1-4
However, traditional diagnostic approaches such as karyotyping
and fluorescence in situ hybridization (FISH), also remain critical
to the complete characterization of AML and a number of important
mutations such as internal tandem duplications (ITD) of Fms-like
tyrosine kinase 3 (FLT3) (FLT3-ITD) and partial tandem duplications
(PTD) ofmixed-lineage leukemia (MLL) (MLL-PTD) genes are difficult
to detect using conventional next-generation sequencing (NGS)-based
approaches.1,5 Furthermore, copy neutral loss-of-heterozygosity
(CN-LOH) events, a frequent and prognostically significant class
of mutations in AML,6-8 are not detectable by mainstream diagnostic
platforms.Althoughwhole genome and exome sequencing can capture
many of the target mutations, they both remain costly, analytically
intensive, and unable to reliably detect translocations and zygosity
changes in their standard formats. Furthermore, they can both fail to
detect low-burden subclonal mutations with clinical significance,
such as those affecting TP53.9 Therefore, there is a pressing need
for a robust and accessible platform that can comprehensively charac-
terize the diverse types of mutations in myeloid malignancies to guide
clinical decision-making.
In order to address this unmet clinical need, we have developed
Karyogene, a one-stop diagnostic method employing targeted capture
followed by NGS coupled with a bespoke suite of novel and recently
developed bio-informatic tools for the simultaneous detection of sub-
stitutions, indels, chromosomal translocations, and genome-wide copy
number and zygosity changes.We describe and validate this diagnostic
platform using 62 AML and 50 MDS diagnostic samples previously
characterized using conventional diagnostic approaches. Our results
show that Karyogene performs remarkably well in detecting these
diverse mutation classes and can also identify novel mutations, in-
cluding anMLL–diaphanous-related formin 2 (DIAPH2) fusion and
CN-LOH of mutations involving DNMT3A R882. The approach
represents a significant advance toward bringing genomics to the
diagnosis of myeloid malignancies and can easily be adapted for use
in other cancers.
Methods
DNA samples
Diagnostic bonemarrow (BM)DNA samples from 62 unselected AML patients
were obtained from 2 centers: Hospital de la Santa Creu I Sant Pau, Barcelona,
Spain and Addenbrooke’s Hospital, Cambridge, United Kingdom. Of these, 24
patients also had paired remission samples. Diagnostic BMDNA samples from
50 MDS patients, enriched for cases with cytogenetic abnormalities, were
extracted from cytogenetic pellets stored at220°C inmethanol/acetic acid at the
Haemato-oncology Diagnostic Service, Addenbrooke’s Hospital and genomic
DNA was extracted using a Qiagen DNeasy Kit as per the manufacturer’s
instructions. Included in the study were also cord blood samples (n 5 7), and
blood granulocyte and mononuclear cell DNA from unselected adults without
evidence of hematologic abnormalities (n 5 33). (See supplemental Table 1,
available on theBloodWeb site, for characteristics of the 181 samples used in the
study). Samples were obtained with written informed consent and appropriate
ethics committee approval (approval reference numbers: 07/MRE05/44 or
CEIC-11/2012, and EC/15/092/4214).
Bait design for targeted DNA capture
Acustom library of 53 613 oligonucleotide baitswas designed usingSureDesign
software (ELID reference: 0479081; SureSelect, Agilent Technologies) to
capture the following: (1) all exons of 49 genes known to be recurrently mutated
in myeloid malignancies (Table 1). The exon co-ordinates were downloaded
from BioMart release 68 (http://www.ensembl.org/biomart/martview/), RefSeq
release 54 (http://www.ncbi.nlm.nih.gov/refseq/), CCDS release 9 (http://www.
ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi), Gencode release 12 (http://www.
gencodegenes.org/releases/12.html), and Vega release 48 (http://vega.sanger.ac.
uk/index.html), and overlapping coordinates were merged into the longest
possible consensus sequence for which overlapping 120-nt baits were created,
starting every 30 bp (supplemental Figure 1A). Baits were designed using
SureDesign to include 10 bp flanking regions at the 59 and 39 ends of each exon
and bait overlap with repetitive regions was limited to a maximum of 20 bp. (2)
Previously identified intronic breakpoints at both partner genes for detection of
PML-RARA t(15;17),CBFB-MYH11 (inv[16]),RUNX1-RUNXT1 t(8;21), and at
the MLL gene for detection of MLL translocations with any partner (Table 1;
supplemental Table 2). These regions were covered with overlapping 120 bp
baits starting every 40 bp (supplemental Figure 1B); and (3) 9111 single
nucleotide polymorphisms (SNPs)withminor allele frequency (MAF) of 0.40 to
0.45 across diverse human population cohorts, spaced on average every 300 kb
on all autosomes and on the X chromosome. Of these, 135 were discarded
because theygave less than10 reads in twoormorenormal samples leaving 8976
for analysis, of which 8673 gave consistent results in normal samples and were
used for copy number calls (see supplemental Methods for details). Each SNP
location was covered by 3 overlapping 120 nt baits (supplemental Figure 1C).
The size of total target region was 2.3 Mbp. The least stringent repeat masking
option was selected in SureDesign to avoid placing baits on highly repetitive or
low complexity regions. The replication of individual baits was adjusted
depending on the guanine-cytosine content of the target regions using the
SureDesign maximize performance bait boosting option for all targets, with the
exception for breakpoint probes where balanced boosting was selected (Agilent
Technologies). For access to the bait design, see https://github.com/karyogene/
diagnostic-tool.
DNA target enrichment and sequencing
DNA fragmentation, library preparation, indexing, and solution phase hybrid
capture were performed according to the manufacturer’s instructions (Agilent
Technologies). The 181 indexed samples were sequenced across 9 lanes of
Illumina HiSeq 2000 (75 bp paired-end) and FASTQ files aligned to GRCh37/
hg19 human reference sequence (2009) using Burrows–Wheeler Alignment
(http://bio-bwa.sourceforge.net/bwa.shtml). All samples were also aligned using
version 0.7.6.2 of the SequenceMapping andAlignment Tool (SMALT) aligner
(http://smalt.sourceforge.net) for the purposes of translocation detection.
Translocation detection using SMALT-finder of inversion and
translocations (FIT)
In order to detect translocation breakpoints, paired-end reads were aligned to the
human reference genome (Hg19) using SMALT version 0.7.6.2, which reports
paired read alignments by individual alignment scores and has a mode with
enhanced sensitivity for “split” read alignments. The exact breakpoints were
identified from chimeric reads using the in-house written software FIT (https://
github.com/gt1/FIT). A minimum of 3 independent supporting chimeric
reads was required to call a translocation (see supplemental Methods for a
more detailed description).
Detection of nt substitutions and indels
Substitutions and indels (small indels) involving exons of the 49 genes studied
herewere detected usingMutation Identification andAnalysis Software (MIDAS),
an in-house perl script previously designed and validated to detect such
mutations without the need for matched normal comparisons.1 Briefly,
MIDAS was adjusted to report positions covered by at least 2 independent
high-quality reads (sequencing and mapping quality .20 and with no
additional mismatches or indels in the same read) reporting a different base
to the reference genome. Mutations near polynucleotide tracks or with a
clear read position or read orientation bias were removed. In the case of
indels, at least 5 independent reads reporting the indel were required in the
tumor sample, as well as the absence of any evidence of the indel in the
normal sample. CORDG1 DNA (normal DNA from a cord blood sample)
was used as a normal sample in all the comparisons. All variants present in
the 1000 Genomes database were removed. NPM1 exon 12 4-nt insertions/
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duplications were also searched for using a highly sensitive and specific
tool we described recently.10 Variant calls supported by a variant allele
frequency (VAF) of $0.05 (5%) were cross-referenced against the
Catalogue of Somatic Mutations in Cancer (COSMIC) database (http://
cancer.sanger.ac.uk/cosmic/). Missense, frameshift, or nonsense mutations
at VAF .0.1 and not present in COSMIC or within 6 10 bases of a
COSMIC mutation were reported only if they affected genes known to be
targeted by somatic mutations at multiple sites throughout their length (ie,
CEBPA, TET2, DNMT3A BCOR, TP53, PHF6, STAG2, RAD21, and
SMC1A). To minimize the likelihood of reporting inherited variants, non-
hotspot mutations were also manually checked to confirm they were
previously reported as somatic and if they were not, we only reported them
if their VAF was ,0.47 or .0.53 (but ,0.98). Mutations were annotated
against the transcript in which the mutation is predicted to have the most
deleterious effect. Annotations for DNMT3A and KIT mutations were
manually changed after mutation calling to match their commonly used
reference transcripts.Mutation calls were comparedwith the knownmolecular
information derived by the diagnostic laboratories using conventional
molecular methods including melt curve analysis, real-time polymerase
chain reaction (PCR), and gel electrophoresis and capillary sequencing
(supplemental Table 3). The MIDAS software can be downloaded from https://
github.com/karyogene/diagnostic-tool.
MLL-PTD and FLT3-ITD detection using novel “tandem
finder” algorithms
MLL can be mutated via intragenic, PTDs involving exons 3-9, 3-10, or 3-11.11
BecauseMLL exon 3 is always involved, we designed theMLL Tandem Finder
(M-TAFI), a tool comparing the relative coverage forMLL exons 3 to 27 in each
sample (supplemental Figure 2). The 2 exons were chosen because of their
large size (exon 3: 2654 bp and exon 27: 4249 bp) and very uniform coverage
ratio in samples lacking MLL-PTD, including those with MLL fusions or
other cytogenetic abnormalities.M-TAFI, a tool based onSAMtools12 (http://
samtools.sourceforge.net and http://www.htslib.org/) is available from https://
github.com/karyogene/diagnostic-tool.
FLT3-ITDs are in-frame duplications of varying length (3 to .200 nt), within
exon 14 or 15 of the gene. They are difficult to detect through analysis of
short-read NGS with conventional bio-informatic tools, mainly because of
misalignment and/or binning of mutant reads. In order to optimize FLT3-ITD
detection, we developed the FLT3 Tandem Finder (F-TAFI), a new bio-
informatic tool that extracts sequences with at least partial mapping to FLT3
exons 14 and 15, and generates an overlap graph equivalent to de novo regional
assembly. This identified instances when overlapping FLT3 sequences
formed “bubbles” or “loops,” indicating the presence of an ITD (supplemental
Methods). The F-TAFI software is available from https://github.com/gt1/
alternatives.
Copy number and LOH analysis using cloneHD
For genome-wide copy number and zygosity analysis, we analyzed 8673 highly
polymorphic SNPs, with an MAF of 0.40 to 0.45 across diverse human
populations (9 ethnic populations over 3 continents; supplemental Table 4) to
maximize the number of informative (heterozygous) individuals across ethnic
groups. Sequencing data from the targeted SNPs were used to derive copy
number and identify areas of LOH using cloneHD, a probabilistic algorithm
designed for subclone reconstruction from data generated by high-throughput
DNA sequencing, that can be used for analysis of copy number, B-allele status,
and single nucleotide variant (SNV) genotype.13 A panel of 40 normal samples
sequenced using the same bait set were used as a control set to standardize for
coverage bias during sequencing and pull-down (supplemental Methods). Copy
number outputs were compared with the results of diagnostic cytogenetic and
FISH data for each patient (supplemental Table 3).
Table 1. Genomic loci captured and analyzed by the Karyogene platform
I. Coding mutations in 49 genes
Gene ID Chromosome Position (Mb)* Gene ID Chromosome Position (Mb)*
MSTP9 1 17.1 WT1 11 32.4
NRAS 1 115.2 MLL 11 118.3
DNMT3A 2 25.5 CBL 11 119.1
DDX18 2 118.5 ETV6 12 11.8
SF3B1 2 198.2 KRAS 12 25.4
IDH1 2 209.1 PTPN11 12 112.9
CBLB 3 105.3 FLT3 13 28.6
GATA2 3 128.1 DIS3 13 73.3
MUC4 3 195.4 IDH2 15 90.6
KIT 4 55.5 CREBBP 16 3.7
TET2 4 106.1 TP53 17 7.6
DDX4 5 55 NF1 17 29.4
CSF1R 5 149.4 SRSF2 17 74.7
NPM1 5 170.8 MUC16 19 8.9
DAXX 6 33.2 CEBPA 19 33.8
ZAN 7 100.3 ASXL1 20 30.9
EZH2 7 148.5 PTPRT 20 40.7
CSMD1 8 2.8 RUNX1 21 36.1
RAD21 8 117.8 U2AF1 21 44.5
JAK2 9 49.8 BCOR X 39.9
PRUNE2 9 79.2 KDM6A X 44.7
WAC 10 28.8 SMC1A X 53.4
PTEN 10 89.6 STAG2 X 123.1
SMC3 10 112.3 PHF6 X 133.5
NUP98 11 3.7
II. Chromosomal rearrangements III. Copy number and zygosity changes
PML-RARA t(15:17) Genome-wide polymorphic SNPs (n 5 9111) with
CBFB-MYH11 inv(16) MAF 0.40 to 0.45 in 3 continental cohorts
RUNX1-RUNXT1 t(8;21)
MLL fusions 11q23 rearrangements
*CRCh37/hg19.
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Validation of somatic mutations: SNVs, indels, duplications,
and translocations
Mutations affecting NPM1, FLT3, CEBPA, IDH1, and WT1 were validated
by comparison with pre-derived diagnostic data. Additionally, a subgroup
of mutations affecting different genes was validated using PCR and MiSeq
as described before10 (supplemental Figure 3). Validation of PML-RARA,
RUNX1-RUNXT1, CBFB-MYH11, andMLL rearrangement calls was by com-
parison of translocation breakpoints with pre-derived cytogenetic and FISH
diagnostic data (supplemental Table 5).
Validation of the MLL-DIAPH2 fusion gene
PCR and real-time PCR with AML DNA and complementary DNA (cDNA),
respectively, were used. DNA primers were: P1: (TAAAATTACAAATG
GAAAGGACA) and P2: (TGTCATTTCACATTCCTCCCA); and cDNA
primerswere P3: (GGAAGTCAAGCAAGCAGGTC) and P4: (CCTTCATGGC
CAAAGTTGTT). PCR products were sequenced using Sanger sequencing.
Results
Sequencing data were aligned using Burrows–Wheeler Alignment, and
separately by SMALT and analyzed as described in Figure 1. Average
coverage was $303 for 94% of target exons and 98% of target
SNPs,with 75%of exons/SNPs covered at$703. Coverage statistics
per exon for each of the 49 genes captured is given in supplemental
Appendix 1.
Substitutions and indels
Using the approach described in “Methods,” we identified 2185 on-
target variants, of which 792 had a VAF $0.05. After excluding
silent mutations and probable inherited variants, we were left with
218 substitutions/indels of which 155 had been previously reported
in myeloid malignancies. Among 62 AML samples, the 4 most common
coding mutations identified affected FLT3 (n 5 18), NPM1 (n 5 13),
DNMT3A (n514),CEBPA (n510), IDH1 (n57), andNRASorKRAS
(n 5 11) (Figure 2; supplemental Table 6). By comparison with con-
ventional diagnostics performed a priori, we detected 13/13 NPM1,
12/12FLT3-ITD (size range, 18 to106bp), 5/5 IDH1R132, 4/4CEBPA,
3/3 MLL-PTD, 2/2 IDH2 R140Q, and 1/1 IDH2R172K mutations. A
number of variants were called that were not reported in COSMIC and
involved genes known to be affected by mutations at multiple positions
(eg,DNMT3A,TET2,CEBPA,RUNX1,NF1,STAG2,PHF6, andZAN).
An unselected set of variants were also validated using PCR followed
by MiSeq sequencing (supplemental Figure 3), as was 1 AML sample
(AML_125_a) with co-existent mutations in IDH1 R132H (VAF 0.23)
and IDH2 R140Q (VAF 0.22), given the reported mutual exclusivity
of IDH1/2 mutations in AML.14 Patients with translocations generally
had fewer coding mutations, although these could be of prognostic
significance (eg, KIT exon 8 mutations in patients with CBFB-MYH11
fusions).15,16Among24AMLpatientswith paired diagnostic-remission
samples, we identified 5 patients with detectable driver mutations
present in the remission sample, involving DNMT3A (32), ASXL1,
IDH2, orRUNX1 (supplemental Table 7). In 4/5 instances, there was
a significant reduction in the VAF at remission, but this was not the
case for the AML74a/AML74b pair in which the VAF of an ASXL1
mutation was not reduced by chemotherapy. Interestingly, the VAFs
of this mutation suggested that it was not part of the leukemic clone
or this may represent an artifact.
Among 50 MDS samples, selected to be enriched for cases with
abnormal karyotypes, themost commonmutations affected TP53 (n5
16), TET2 (n5 18), SRSF2 (n5 8), and ASXL1 (n5 11). Of note, 6 of
the 11ASXL1mutations identified inourMDSsampleswere frameshift
mutations at c.1927 due to an insertion of a guanine (G) leading to p.
G643fs*15 (equivalent to c.1934dupG; p.G646GWfs*12). Although
we did not identify this mutation in any of the 40 normals sequenced, it
is possible this result may be artifactual as reported for G insertions in
this G-rich region.17 Notably, all cases with co-existing deletions
of chromosome 5 and of 1 other chromosome (eg, chromosome 7) also
harbored mutations in TP53. Specific patterns of mutational co-
occurrence such as SRSF2 andTET2, and ofmutual exclusivity among
mutations affecting spliceosome genes were observed as pre-
viously described18,19 (Figure 2).
CloneHD MIDAS F-TAFI M-TAFI SMALT-FIT
Copy  number &
zygosity changes
SNVs &
indels
FLT3-ITD MLL-PTD Translocations
Targeted Capture
(RNA baits)
Genomic DNA
Sequencing
(HiSeq – 75bp PE)
Bioinformatic
analysis
Figure 1. Outline of the Karyogene workflow. Geno-
mic DNA was processed to capture target loci using RNA
baits and sequenced on a HiSeq 2000 sequencer as
described in “Methods.” Sequencing data were mapped
to the genome and analyzed through the indicated
software to detect the corresponding types of mutations.
The bait design underpinning these is described in supple-
mental Figure 1. HD, high definition; PE, paired-end.
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Detection of FLT3-ITD and MLL-PTD
FLT3-ITD mutations are prognostically important,20-22 but difficult
to identify reliably using conventional short-read NGS data.1,2,5
To address this, we developed F-TAFI, a novel bio-informatic
tool that uses a de novo graph-based assembly-like approach to
identify sequence “loops” within FLT3 exons 14 and 15, and this
detected all 12 cases of FLT3-ITDs in our samples without false
positives among 171 FLT3-ITD–negative samples (Figure 2;
supplemental Methods). MLL-PTD is also associated with an
adverse prognosis23-25 and cannot be detected by standardmutational
callers, because it does not change the exonic nt sequence. To detect
these mutations, we developed M-TAFI, a distinct bio-informatic
approach used to derive an MLL exon3/exon27 coverage ratio from
our sequencing data. In our analysis, M-TAFI detected all 3 known
cases ofMLL-PTD in our 181 samples, without false-positive results
(supplemental Figure 4).
Copy number and LOH analysis using cloneHD
To detect copy number and LOH changes, we captured and analyzed
sequencing data from highly polymorphic SNPs distributed across all
chromosomes except Y using cloneHD.13 The depth at each SNP locus
(supplemental Table 8) was calculated as the average depth over the
segment targeted in the pull-down minus 10 bp at either end. We
further selected for each sample a subset of SNPs that were germ line
heterozygous. These read depth, and SNP data were used to generate
genome-wide copy number and zygosity values for each sample
(supplemental Methods), which were compared with the results of
diagnostic cytogenetic andFISHdata.This identified44/47clinically
significant copy number changes that were present in$20% of cells
at diagnosis, namely del(5)/del(5q) (18/18), del(7)/del(7q) (8/8),
del(20q) (6/7), trisomy 8 (10/12), del(13q) (1/1), and del(17p) (1/1)
(Figure 2; supplemental Figure 5). Additionally, we identified 3
further cases of 17p deletion, which were not detected cytogenet-
ically (2 of which also harbored TP53 mutations) as well as many
smaller genomic deletions and amplifications (Figure 2; supplemental
Figure 5).
Furthermore, we identified 18 CN-LOH events in 15 samples,
including11cases involving knownsomatic drivermutations (3TP53,
3 TET2, 2 DNMT3A R882, 1 FLT3-ITD, 1 NRAS, and 1 EZH2)
(Figure 2; supplemental Figure 5). In 9 of these 11 cases, the VAF
of these mutations was .70% indicating duplication of the
mutated allele. The 2 cases of chromosome 2p CN-LOHwere seen
in association with DNMT3A R882C (VAF 0.97) (Figure 3), and
R882H (VAF 0.72) mutations were of particular interest because
we could not identify previous published reports of CN-LOHaffecting
DNMT3A R882 mutations. Additional examples of cloneHD outputs
are shown in supplemental Figure 6.
           ZAN
                  del(7)/del(7q)
                  del(5)/del(5q)
del(13q)
del(20q)
SRSF2
WT1
AML n = 62 MDS n = 50
Other large CNA
trisomy 8
del(17p)
CEBPA
Mutation identified at diagnosis detected Mutations identified at diagnosis not detected
Mutation detected
CNA in <20% cells by cytogenetics/FISH
CN- LOH
>1 mutation in the same gene
                 *PML-RARA
     * CBFB-MYH11
     *RUNX1-RUNXT1
*MLL-X fusions
       *NPM1
     RUNX1
    CREBBP
   GATA2
DNMT3A
        *IDH2
         *IDH1
         TET2
*FLT3-TKD
  *FLT3-ITD
             KIT
              NRAS/KRAS
                  CBL
         PHF6
    PTPN11
        BCOR
           NF1
       JAK2
       ASXL1
                EZH2
        *MLL-PTD
            MLL
        SMC3
     SMC1A
              STAG2
      U2AF1
RAD21
TP53
         CSF1R
Activated Signalling
Chromosomal
rearrangements
Tumor Suppressor
DNA Methylation
Myeloid TFs
SF3B1
Cohesins
Copy number
aberrations
Spliceosomes
Substitutions
& indels
Key:
Chromatin modifiers
CN-LOH affecting mutation
Figure 2. Genomic characterization of myeloid malignancies using Karyogene. Individual AML (n 5 62) and MDS (n 5 50) samples are represented in columns and
genetic mutations in rows. AML samples were unselected whereas MDS samples were pre-selected to harbor chromosomal copy number changes. Mutations are grouped
into chromosomal translocations (top), substitutions and indels (middle), CNAs (bottom), and CN-LOH events (bottom row). Clinically relevant CNAs are depicted in separate
rows and “other large CNAs” refers to changes affecting regions larger than 3 mbp (described in detail in supplemental Figure 3). The presence of mutations in different
contexts is indicated according to the key (bottom left). TF, transcription factor.
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Identification of AML-associated chromosomal translocations
and identification of the novel fusion gene MLL-DIAPH2
We used targeted pull-down to capture previously identified re-
current breakpoint regions and analyzed sequence reads mapping
to these regions using the SMALT-FIT platform. This detected all
instances of one of the four common AML-associated transloca-
tions, namely t(15;17)/PML-RARA (9/9), inv(16)/CBFB-MYH11
(8/8), t(8;21)/RUNX1-RUNXT1 (4/4), and MLL fusions (8/8); as
well as 1 patient with anMLL translocation not identified at diagnosis
(see supplemental Table 5 for coordinates of all 30 breakpoints
identified in this study). The partner gene was identified in all 9 cases
withMLL fusions, with 7/9 involving well-known partners. In 1 case
the partner, FLNA, has been described only in 2 cases of infant AML,
but never in adult,26,27 and in another, the partnerDIAPH2, was novel
(Figure 4). Therewere no false-positive results among the 181 samples
analyzed.
Discussion
WedescribeKaryogene, a genomic analysis platformbased on targeted
DNA capture followed by sequencing and bespoke bio-informatic
analysis based on open-source software tools. We show that the
platform efficiently identifies all major categories of somatic
mutations found in AML and MDS without the requirement for a
matched normal sample as a comparator.
With regards to substitutions and indels, we accurately detected all
pre-detected instances of NPM1, FLT3, IDH1, IDH2, and CEBPA
mutations, as well as other nt substitutions and indels with established
prognostic significance including those affecting TP53, DNMT3A,
ASXL1, KIT, SRSF2, and SF3B1. Notably, this was done by com-
parisonwith the same unmatched normal comparator for all samples,
as would be practical in a diagnostic context. Our approach to the
filtration of SNVs and indels reduced the likelihood of misreporting
inherited variants as somatic as much as possible; although such an
event could not be completely ruled out without the use of paired
germ line DNA as amatched comparator. Additionally, we show in a
subset analysis of 24 samples with a matched “normal” comparator
(remission BM), that such a paired comparison risks filtering out key
leukemic mutations from the diagnostic sample. In fact, we found
that the comparison between the 24 matched diagnosis-remission
pairs in our study, missed clinically important mutations in 5/24
cases affectingDNMT3A (32), IDH2, RUNX1, and ASXL1, as these
mutations persisted in the remission sample. Additionally, using our
novel bio-informatic approaches for detecting tandem duplications,
we correctly identified all instances of FLT3-ITD and MLL-PTD in
our samples;mutations that have previously proven difficult to detect
using conventional NGS bio-informatic approaches.1,2,5
A number of different approaches have been described for the
detection of chromosomal translocations in NGS sequencing data28,29
by searching for discordant paired-end reads and in some cases, also
for split reads. Many of these algorithms display very good sensitivity
in detecting translocations and inversions in mappable parts of the
genome, but perform lesswellwhen repetitive regions are involved and
oftenhave a lowspecificity.29 In order tomaximize the accuracyof calls
and reach the level required for clinical diagnosis, we focused on
detecting the 4 most common translocations in AML/MDS (Table 1),
which represent .80% of AML-associated translocations and
.90% of those with clinical significance.30 This enabled us to
limit the size of our bait-set and to develop a targeted algorithm
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(SMALT-FIT), which achieved 100% specificity and sensitivity
for their detection. Furthermore, we identified 9/9 MLL fusion
partners, including the novel partner DIAPH2. DIAPH2, located
on Xq21, encodes a member of the diaphanous subfamily of the
formin homology family of proteins, which are key regulators of
fundamental actin-driven cellular processes conserved from yeast
to humans.31,32 Formins have been linked to the progression of
cancer,33,34 including hematologic cancer35,36 and even myeloid
malignancy37; however, DIAPH2 itself has not previously been specif-
ically linked to oncogenesis.
Copy number abnormalities/aberrations (CNAs) and zygosity
changes are key determinants of prognosis in many cancers, in-
cluding AML and MDS. In current diagnostic practice, large-scale
genomic gains and losses are detected using karyotyping or FISH,38
but more subtle changes go undetected, as does CN-LOH. To enable
the detection of these mutations as part of a single diagnostic tool, we
selected 9111 SNPs for targeted capture. These were chosen to have
high MAFs (0.40 to 0.45) in multiple human populations, to increase
the likelihood of heterozygosity across ethnic groups. Reads mapping
to these SNPs were analyzed using cloneHD to derive genome-wide
copy number estimates without the need for a matched normal/
remission sample. To test the effectiveness of our approach, we
deliberately studied several MDS cases with chromosomal abnormal-
ities (Figure 2) and successfully identified 93% (44/47) of clinically
relevant large chromosomal abnormalities involving .20% of
cells, namely all such cases of del(5)/del(5q) (18/18) and del(7)/
del(7q) (8/8), and the majority of del(20q) (6/7), trisomy 8 (10/12),
del(13q) (1 of 1), and del(17p) (1 of 1). The 3missed CNAs (2 cases
of trisomy 8 and 1 case of del20q) affected #35% of cells and 2/3
were detected using FISH probes rather than karyotyping, leaving
someuncertainly about the extent of the genomic gain/loss. In addition,
we identified several smaller areas of deletions or amplifications in-
cluding 3 cases of del(17p), which were not detected cytogenetically
(Figure 2; supplemental Figure 5).
Furthermore, we detected several CN-LOH mutations, often in-
volving (duplicating) mutations in genes such as TP53 (17p), TET2
(4q), and FLT3-ITD (13q). Among these, we identified 2 cases of
CN-LOHat2p,1 involvingDNMT3AR882Cinachronicmyelomonocytic
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indicating the DNA breakpoint regions in MLL intron 10 and DIAPH2 intron 4 in this patient with a t(X;11)(q13;q23). (B) Structure of the MLL-DIAPH2 fusion gene verified
using PCR amplification and Sanger sequencing of leukemic DNA using primers 1 and 2 (p1 and p2) and cDNA using primers 3 and 4 (p3 and p4). Gel electrophoresis
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leukemia (VAF 0.97) (Figure 3) and the other, aDNMT3AR882H in an
AML (VAF 0.72). Homozygosity for somatic DNMT3A non-R882
mutationshasbeen reported inAMLinassociationwithchromosome2p
CN-LOH.14,39 However,DNMT3AR882mutations are thought to have
dominant negative effects on wild-type expression40 and therefore are
not normally found in a homozygous or compound heterozygous state,
despite representing 60%of allDNMT3Amutations inAML.14,41,42 In a
recent paper, only 1 of 172 cases of DNMT3A R882H or R882C had a
VAF .0.6.42 The finding that CN-LOH can sometimes duplicate
R882 mutations indicates that homozygosity at this codon is not
detrimental to leukemic cells as has been hypothesized. In fact,
another possible case of R882 homozygosity was reported
recently.42
In conclusion,we report amethodology for the integrateddiagnostic
work-up of myeloid malignancies, capable of capturing the majority
of clinically significant somaticmutations in a single assay andwithout
the need for a matched normal sample, while also enabling the
identification of previously undescribed mutations such as novelMLL
gene fusions. Importantly, although here we sequenced 181 samples
across 9 lanes of a high-throughput platform (HiSeq 2000), smaller
numbers of samples can be processed in an identical way and
sequenced by lower-throughput sequencers (eg, MiSeq, NextSeq,
or other). This would allow a diagnostic laboratory to study 5 to 20
samples once or twice weekly and reduce “sample to report”
turnaround time to less than 14 days (less than 10 days for twice
weekly runs), thus integrating comfortably into a clinical service.Also,
the approach can be easily adapted for use in other malignancies by
changing the gene targets and, if relevant, the chromosomal break-
points for capture. The set of polymorphic SNPs validated here can be
used unaltered for the detection of copy number and LOHmutations in
other cancers and even for the detection of LOH in constitutional
disorders, although bespoke selection of SNPs or an increase in
sequencing depth could improve detection of smaller areas of copy
number change within selected regions or of smaller subclones. The
ability of Karyogene to detect copy number changes with a sensitivity
that is at least equivalent to conventional karyotyping, which is
expensive and labor-intensive, is an important advantage that is likely
to make cost calculations favorable for most integrated diagnostic
laboratories. Karyogene represents an important advance that can
accelerate the introduction of genomics to clinical diagnosis.
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